Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial.

Michele Reni,Hedy L. Kindler,Pascal Hammel,Eric Van Cutsem,Teresa Macarulla,Michael J. Hall,Joon Oh Park,Daniel Hochhauser,Dirk Arnold,Do-Youn Oh,Anke Reinacher-Schick,Giampaolo Tortora,Hana Algül,Eileen M. O’Reilly,David McGuinness,Karen Cui,Katia Schlienger,Gershon Y. Locker,Talia Golan

Adverse events (AEs) with maintenance olaparib in patients with a germline BRCA mutation (gBRCAm) and metastatic pancreatic cancer (mPaC): Phase III POLO trial.

2020

Michele Reni
Hedy L. Kindler
Pascal Hammel
Eric Van Cutsem
Teresa Macarulla
Michael J. Hall
Joon Oh Park
Daniel Hochhauser
Dirk Arnold
Do-Youn Oh
Anke Reinacher-Schick
Giampaolo Tortora
Hana Algül
Eileen M. O’Reilly
David McGuinness
Karen Cui
Katia Schlienger
Gershon Y. Locker
Talia Golan

686Background: In POLO (NCT02184195), maintenance olaparib was well tolerated and led to a significant progression-free survival benefit vs placebo in patients with a gBRCAm and mPaC whose disease ...

Keywords:

Internal medicine
Metastatic pancreatic cancer
Adverse effect
Germline
Medicine
BRCA mutation
Olaparib
Oncology
Pathology
in patient
Placebo
Disease

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations